Strs Ohio reduced its position in Pfizer Inc. (NYSE:PFE) by 6.1% in the third quarter, Holdings Channel.com reports. The fund owned 2,707,004 shares of the biopharmaceutical company’s stock after selling 176,514 shares during the quarter. Strs Ohio’s holdings in Pfizer were worth $97,262,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. Bath Savings Trust Co boosted its holdings in Pfizer by 3.4% in the 2nd quarter. Bath Savings Trust Co now owns 17,217 shares of the biopharmaceutical company’s stock valued at $746,000 after purchasing an additional 564 shares during the period. Cox Capital Mgt LLC lifted its holdings in shares of Pfizer by 1.5% during the 2nd quarter. Cox Capital Mgt LLC now owns 37,986 shares of the biopharmaceutical company’s stock worth $1,646,000 after acquiring an additional 565 shares during the period. Thomasville National Bank lifted its holdings in shares of Pfizer by 4.1% during the 2nd quarter. Thomasville National Bank now owns 76,628 shares of the biopharmaceutical company’s stock worth $3,319,000 after acquiring an additional 3,001 shares during the period. Park National Corp OH lifted its holdings in shares of Pfizer by 27.6% during the 2nd quarter. Park National Corp OH now owns 252,546 shares of the biopharmaceutical company’s stock worth $10,941,000 after acquiring an additional 54,642 shares during the period. Finally, Deane Retirement Strategies Inc. lifted its holdings in shares of Pfizer by 1.8% during the 2nd quarter. Deane Retirement Strategies Inc. now owns 51,699 shares of the biopharmaceutical company’s stock worth $2,240,000 after acquiring an additional 894 shares during the period. Institutional investors own 71.66% of the company’s stock.
In other news, major shareholder Pfizer Inc acquired 50,000 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $900,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott Gottlieb acquired 3,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the transaction, the director now owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm had revenue of $13.26 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the prior year, the company posted $0.77 EPS. The company’s revenue was down 1.5% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.82 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 3.96%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.
A number of analysts have recently weighed in on PFE shares. JPMorgan Chase & Co. upped their price target on shares of Pfizer from $37.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, September 19th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a report on Tuesday, October 1st. UBS Group reaffirmed a “neutral” rating and set a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. Bank of America started coverage on shares of Pfizer in a report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price target for the company. Finally, ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Twelve analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Pfizer has a consensus rating of “Hold” and an average target price of $44.47.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: Ex-Dividend
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.